Bio Medica Laboratories IPO
Market Sentiment
IPO Details
IPO Reservation
Market Lot Size
Financial Analysis
| Metric | 2023 | 2024 | 2025 | Nov 2025 |
|---|---|---|---|---|
| Revenue | 16.25 | 15.34 | 38.33 | 28.63 |
| Expense | 15.80 | 11.69 | 25.18 | 16.95 |
| Profit (PAT) | 0.33 | 2.50 | 9.79 | 8.66 |
| Total Assets | 17.57 | 19.53 | 39.12 | 65.17 |
| Company | P/E | EPS |
|---|---|---|
| Zenotech Laboratories Limited | - | 0.92 |
| Shukra Pharmaceuticals Limited | 47.57 | 0.22 |
Promoters: Mr. Mukesh Mehta and Mr. Pradeep Mehta
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 91,80,001 | 99.99% |
Strengths & Risks
- Strong institutional (QIB) demand — 15.9x.
- Revenue grew 150% in the latest reported year.
- Solid profit margin — 25.5%.
- Strong return on equity — 100%.
- Mostly fresh capital — proceeds fund the company's growth, not an exit.
- Elevated leverage — debt/equity of 1.02.
Auto-generated from live GMP, subscription, valuation and financial data. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Bio Medica Laboratories is one of the leading manufacturers of parenteral medicines (injectable products) in India. The firm has been involved in developing a wide range of parenteral medicines targeting both human and animal needs. They manufacture generic medicines in the form of Liquid injections and dry powder injections, which come in various forms of packaging like ampoules and vials.
| Purpose | Amount (Cr) |
|---|---|
| Repayment of Loan | 7.25 |
| Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises | 24.81 |
| General Corporate Purpose | - |
Resources & Documents
Bio Medica Laboratories Ltd., Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate (Indore),, Indore, Madhya Pradesh, 452015
Bio Medica Laboratories has set a price band of Rs 132–Rs 139 per share for an issue size of Rs 52 crore. The stock listed with a 20.00% discount versus its issue price on May 29, 2026.
Bio Medica Laboratories is one of the leading manufacturers of parenteral medicines (injectable products) in India. The firm has been involved in developing a wide range of parenteral medicines targeting both human and animal needs.
The issue is promoted by Mr. Mukesh Mehta and Mr. Pradeep Mehta with Narnolia Financial Services Ltd. acting as lead manager. Net proceeds will primarily be used towards Repayment of Loan (Rs 7 crore) and Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises (Rs 25 crore).
Grey market is quoting a discount of Rs -6 (-4.3% over issue price), down Rs 10 from the previous session. Final subscription data records overall subscription at 2.31x, retail at 2.92x, QIB at 15.94x, NII at 1.41x.
On fundamentals, the company is posting revenue growth of 149.9%, a profit margin of 25.5%, return on equity of 99.6% in its most recent reported period. Listed peers in this segment include Shukra Pharmaceuticals Limited (P/E 47.57x) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
Our data-driven engine currently flags this issue as an Avoid view — key indicators are weak enough that the risk-reward looks unfavourable for now. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Understanding Grey Market Premium (GMP)
The Grey Market Premium (GMP) is an unofficial indicator of how an IPO's shares are trading in the grey market before they are officially listed on a stock exchange. It reflects investor sentiment and demand for the IPO shares ahead of listing day.
How does it work? The grey market is an informal, over-the-counter market where investors buy and sell IPO shares before the official listing date. If an IPO has a positive GMP, it suggests that investors expect the stock to list above its issue price. A negative GMP indicates expectations of a listing below the issue price.
Example: If an IPO has an issue price of ₹100 and the GMP is ₹50, the expected listing price would be approximately ₹150 (issue price + GMP). This translates to an estimated listing gain of 50%.
Factors that influence GMP:
- Subscription levels — Higher subscription typically drives GMP up
- Market conditions — Bullish markets tend to boost GMP across all IPOs
- Company fundamentals — Strong financials and growth potential attract premium
- Industry sentiment — Positive outlook for the sector can increase demand
- IPO pricing — Reasonably priced IPOs relative to peers tend to command higher GMP
Disclaimer: GMP is an unofficial metric from the grey market and is not regulated by SEBI or any stock exchange. GMP values fluctuate frequently and should not be the sole basis for investment decisions. Always consider company fundamentals, financial health, and your own risk appetite before investing in any IPO.
Related IPO
No comments yet. Be the first to share your opinion!